SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals, Inc. announced today the initial public offering of 4,000,000 shares of common stock at a price of $6 per share. SGX Pharmaceuticals common stock is expected to begin trading on the NASDAQ National Market under the trading symbol SGXP on Wednesday February 1, 2006. All shares are being offered by SGX Pharmaceuticals.
CIBC World Markets Corp. and Piper Jaffray & Co. are acting as joint book- running managers, and JMP Securities LLC is acting as co-manager of the offering. SGX Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares to cover over-allotments, if any.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 31, 2006. This offering is being made by means of written prospectus. Copies of the final prospectus relating to the offering may be obtained by contacting CIBC World Markets Corp. by email at useprospectus@us.cibc.com or by fax at 212-667-6136 and from Piper Jaffray & Co., U.S. Bancorp Center, 800 Nicollet Mall, Minneapolis, Minnesota 55402 or by fax at 612-303-1070.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About SGX Pharmaceuticals
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics.
SGX Pharmaceuticals, Inc.
CONTACT: Jason I. Spark, Investor and Media Relations of Porter NovelliLife Sciences, +1-858-527-3491 or jspark@pnlifesciences.com, for SGXPharmaceuticals, Inc.
